The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent “in-tumour” chemotherapy to pancreatic ductal adenocarcinoma

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks
Luned M. Badder1, James A. Davies1, Valerie S. Meniel2, Mahulena Marušková1, Beatriz Salvador-Barbero2, Rebecca J. Bayliss1,Toby J. Phesse2,3, Catherine Hogan2and Alan L. Parker1,4✉
1Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK.2European Cancer Stem Cell Research Institute, School of Biosciences,Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.3The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.4Systems Immunity University Research Institute, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK.email: ParkerAL@cardiff.ac.ukwww.nature.com/bjcBritish Journal of Cancer1234567890();,:

Please sign in or register for FREE

If you are a registered user on WORC.Community, please sign in